Our core product candidate, STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. We are developing STP705 for NMSC including isSCC, dermal fibrosis and solid liver tumors.

STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC).

Our key product candidate STP707 is, like STP705, a dual TGF-ß1/COX-2 inhibitor that uses our PNP delivery platform. Whereas STP705 uses a formulation of our PNP delivery platform optimized for local administration (i.e., directly to the site of disease), STP707 uses a formulation of our PNP delivery platform optimized for systemic administration. Thus, STP707 may be administered intravenously for treatment systemically, including solid tumor or fibrotic tissue in the liver or lung.

Looking beyond our initial target indications for local administration for STP705, we are developing STP707 for the treatment of liver cancer, multiple solid tumors and liver fibrosis via systemic administrations as well as for treatment of lung cancer and lung fibrosis. 

STP355 comprises siRNA simultaneously targeting TGF-ß1 and VEGFR2, a target gene well-validated for its involvement in tumor angiogenesis and metastasis, formulated using our PNP delivery platform for systemic administration. We are developing STP355 for the treatment of multiple cancer types, including breast cancer, melanoma and colorectal cancer. We plan to file an IND for STP355 in the U.S. in the first half of 2022. 

STP369 comprises siRNAs targeting BCL-xL and MCL-1, which are both validated tumorigenesis-associated genes, and formulated with our PNP delivery platform for intravenous or intra-tumoral injection administration. We are developing STP369 for the treatment of head and neck cancer and bladder cancer. We are also exploring use of STP369 in combination therapy with platinum-based chemotherapy (cisplatin) due to its widespread use in treating patients to evaluate the potential for STP369 to improve the efficacy of cisplatin or replace its use. We anticipate filing an IND in the second half of 2022. 

STP779 comprises siRNA targeting TGF-ß1 and SULF-2, another validated tumorigenesis-associated gene, formulated with our PNP delivery platform for systemic administration. We are developing STP779 for the treatment of liver cancer, lung cancer and pancreatic cancer. We maintain the global rights to develop and commercialize STP779.  

STP902 comprises siRNA targeting RAF-1, a validated tumorigenesis-associated gene, formulated with our PNP delivery platform for intravenous and intra-tumoral injection; administration. We are developing STP902 for the treatment of breast cancer. We maintain the global rights to develop and commercialize STP902.